astma patiënten Asthma respiratory disorder
Conditions
Interventions
None listed
Sponsors
Erasmus MC, Universitair Medisch Centrum Rotterdam
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: In order to be eligible to participate in this study, a subject must meet one of the following criteria: - Diagnosis of asthma confirmed by at least one of the following as assessed at least once during the 5 past years before the study: - 1. Reversibility to β2-agonists as shown by an increase from baseline in FEV1>= 12% predicted and >= 200 ml after 400 µg inhaled salbutamol or equivalent; - 2. Bronchial hyper-responsiveness (BHR) to metacholine (PD 20% ((PEFmax - PEFmin)/PEFmax) over a period of 14 days. - 4. Fall in FEV1>12% and >200ml when tapering of treatment (ICS, oral steroid, LABA and/or LTRA). ;We will include patients diagnosed with asthma and a recent (
Exclusion criteria
Exclusion criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study:;- received systemic corticosteroid therapy (>= 7.5 mg/kg) within three months prior to inclusion; - no use of inhaled corticosteroids and β2-agonists - BMI > 35; - Smoking > 10 pack years; - Other diseases which could influence pulmonary function and/or the immune system such as: o A possible infection of the upper- or lower respiratory tract 4 weeks prior to the collection of materials; o Chronic obstructive pulmonary disorder (COPD) in the medical history; o Auto-immune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), myasthenia gravis or Goodpasture*s syndrome; o Malignancies; o Human immunodeficiency virus (HIV); o Pregnancy; o Other allergies except for allergic rhinitis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cell numbers and activation of Th subsets, DCs, ILC2s and granulocytes will be determined in peripheral blood and induced sputum of controlled, partly controlled and uncontrolled asthma patients and healthy controls. | — |
Secondary
| Measure | Time frame |
|---|---|
| - To compare the differences in activation status in DCs, and to identify correlations with immunological and clinical disease phenotype - To compare the differences in activation status in T cell subsets, and to identify correlations with immunological and clinical disease phenotype - To establish whether T helper cell polarization by DCs is altered in asthma patients - To find correlations between ILC2 numbers and characteristics and immunological and clinical disease phenotype | — |
Countries
Netherlands
Outcome results
None listed